Weekend of Cancer Data at AACR Ahead of ASCO (ALTH, AMGN, ARIA, ARRY, AZN, BIIB, CELG, CRIS, IMMU, IMGN, INFI, MEDX, MNTA, ONCY, PFE, PCYC, SUPG, TELK, THLD)

Health and Healthcare

Published: April 17, 2009 2:05 pm

Last Updated: April 17, 2009 3:30 pm

This weekend will be a potentially important oncology and cancer news weekend for drug and biotech stocks. The American Association for Cancer Research Meeting will actually have a 100th annual meeting, and some traders and investors may be using this as a preview for what lies ahead at the American Society of Clinical Oncology (ASCO) annual meeting in a month. The following companies which are presenting data:

Allos Therapeutics, Inc. (NASDAQ: ALTH)
Amgen (NASDAQ: AMGN)
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA)
Array BioPharma, Inc. (NASDAQ: ARRY)
AstraZeneca’s (NYSE: AZN) Medimmune unit
Biogen Idec Inc. (NASDAQ: BIIB)
Celgene Corporation (NASDAQ: CELG)
Curis, Inc. (NASDAQ: CRIS)
Immunomedics, Inc. (Nasdaq: IMMU)
ImmunoGen, Inc. (Nasdaq: IMGN)
Infinity Pharmaceuticals, Inc. (NASDAQ: INFI)
Medarex, Inc. (Nasdaq: MEDX)
Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA)
Oncolytics Biotech, Inc. (NASDAQ: ONCY)
Pfizer (NYSE: PFE)
Pharmacyclics, Inc. (NASDAQ: PCYC)
SuperGen Inc. (NASDAQ:SUPG)
Telik, Inc. (Nasdaq: TELK)
Threshold Pharmaceuticals, Inc. (Nasdaq: THLD)

You can see a full summary of the data being presented at BioHealthInvestor.com site. There will be others presenting data this weekend, and these were from the press releases of the meeting ahead of time.

JON C. OGG

Are You Ahead, or Behind on Retirement? (sponsor)

If you’re one of the over 4 Million Americans set to retire this year, you may want to pay attention. Many people have worked their whole lives preparing to retire without ever knowing the answer to the most important question: are you ahead, or behind on your retirement goals?

Don’t make the same mistake. It’s an easy question to answer. A quick conversation with a financial advisor can help you unpack your savings, spending, and goals for your money. With SmartAsset’s free tool, you can connect with vetted financial advisors in minutes.

Why wait? Click here to get started today!